201 related articles for article (PubMed ID: 22294017)
21. Rosuvastatin and the statin wars--the way to peace.
Meyboom RH; Edwards IR
Lancet; 2004 Dec 4-10; 364(9450):1997-9. PubMed ID: 15582043
[No Abstract] [Full Text] [Related]
22. Use of multiple international healthcare databases for the detection of rare drug-associated outcomes: a pharmacoepidemiological programme comparing rosuvastatin with other marketed statins.
García Rodríguez LA; Herings R; Johansson S
Pharmacoepidemiol Drug Saf; 2010 Dec; 19(12):1218-24. PubMed ID: 20922707
[TBL] [Abstract][Full Text] [Related]
23. Short-term memory loss associated with rosuvastatin.
Galatti L; Polimeni G; Salvo F; Romani M; Sessa A; Spina E
Pharmacotherapy; 2006 Aug; 26(8):1190-2. PubMed ID: 16863497
[TBL] [Abstract][Full Text] [Related]
24. Successful desensitization to rosuvastatin in a patient with a history of anaphylaxis to multiple statins.
Khan FS; Stewart DK; Brunzell JD; Natrajan KM; Castells MC; Henderson WR; Ayars AG
J Allergy Clin Immunol; 2013 Jan; 131(1):234-6. PubMed ID: 23177998
[No Abstract] [Full Text] [Related]
25. Rosuvastatin in patients with elevated C-reactive protein.
Mak KH; Chan ES
N Engl J Med; 2009 Mar; 360(10):1039-40; author reply 1041-2. PubMed ID: 19271274
[No Abstract] [Full Text] [Related]
26. Effect of rosuvastatin on fatigue in patients with heart failure.
Perez AC; Jhund P; Preiss D; Kjekshus J; McMurray JJ
J Am Coll Cardiol; 2013 Mar; 61(10):1121-2. PubMed ID: 23473415
[No Abstract] [Full Text] [Related]
27. Severe rhabdomyolysis due to rosuvastatin in a liver transplant subject with human immunodeficiency virus and immunosuppressive therapy-related dyslipidemia.
Moreno A; Fortún J; Graus J; Rodriguez-Gandía MA; Quereda C; Pérez-Elías MJ; Nuño J; Wikman P; Moreno S; Bárcena R
Liver Transpl; 2011 Mar; 17(3):331-3. PubMed ID: 21384516
[TBL] [Abstract][Full Text] [Related]
28. Reversible acute hepatitis induced by rosuvastatin.
Oteri A; Catania MA; Russo A; Salvo F; Giacci L; Caputi AP; Polimeni G
South Med J; 2008 Jul; 101(7):768. PubMed ID: 19209117
[No Abstract] [Full Text] [Related]
29. The safety of rosuvastatin in comparison with other statins in over 100,000 statin users in UK primary care.
García-Rodríguez LA; Massó-González EL; Wallander MA; Johansson S
Pharmacoepidemiol Drug Saf; 2008 Oct; 17(10):943-52. PubMed ID: 18425988
[TBL] [Abstract][Full Text] [Related]
30. Rosuvastatin and vitamin D: might there be hypovitaminosis D on JUPITER?
Goldstein MR; Mascitelli L; Pezzetta F
Int J Cardiol; 2010 Dec; 145(3):556-7. PubMed ID: 20557956
[No Abstract] [Full Text] [Related]
31. Safety of rosuvastatin.
Shepherd J; Hunninghake DB; Stein EA; Kastelein JJ; Harris S; Pears J; Hutchinson HG
Am J Cardiol; 2004 Oct; 94(7):882-8. PubMed ID: 15464670
[TBL] [Abstract][Full Text] [Related]
32. McArdle disease with rhabdomyolysis induced by rosuvastatin: case report.
Lorenzoni PJ; Silvado CE; Scola RH; Luvizotto M; Werneck LC
Arq Neuropsiquiatr; 2007 Sep; 65(3B):834-7. PubMed ID: 17952291
[TBL] [Abstract][Full Text] [Related]
33. Rosuvastatin-associated adverse effects and drug-drug interactions in the clinical setting of dyslipidemia.
Kostapanos MS; Milionis HJ; Elisaf MS
Am J Cardiovasc Drugs; 2010; 10(1):11-28. PubMed ID: 20104931
[TBL] [Abstract][Full Text] [Related]
34. Takotsubo cardiomyopathy with involvement of delayed-onset rhabdomyolysis and acute kidney injury after rosuvastatin treatment.
Kamada T; Hayashi M; Yokoi H; Fujiwara W; Yoshikawa D; Mukaide D; Sugishita Y; Yoshinaga M; Ito T; Ozaki Y; Izawa H
Intern Med; 2015; 54(1):31-5. PubMed ID: 25742890
[TBL] [Abstract][Full Text] [Related]
35. Should rosuvastatin be withdrawn from the market?
Cohen JS
Lancet; 2004 Oct 30-Nov 5; 364(9445):1579; discussion 1579-80. PubMed ID: 15519624
[No Abstract] [Full Text] [Related]
36. Safety of rosuvastatin: update on 16,876 rosuvastatin-treated patients in a multinational clinical trial program.
Shepherd J; Vidt DG; Miller E; Harris S; Blasetto J
Cardiology; 2007; 107(4):433-43. PubMed ID: 17363845
[TBL] [Abstract][Full Text] [Related]
37. Should rosuvastatin be withdrawn from the market?
Florentinus SR; Heerdink ER; Klungel OH; de Boer A
Lancet; 2004 Oct 30-Nov 5; 364(9445):1577; author reply 1578-9. PubMed ID: 15519621
[No Abstract] [Full Text] [Related]
38. Should rosuvastatin be withdrawn from the market?
Kastelein JJ
Lancet; 2004 Oct 30-Nov 5; 364(9445):1577-8; author reply 1578-9. PubMed ID: 15519620
[No Abstract] [Full Text] [Related]
39. Gynecomastia possibly induced by rosuvastatin.
Oteri A; Catania MA; Travaglini R; Russo A; Giustini SE; Caputi AP; Polimeni G
Pharmacotherapy; 2008 Apr; 28(4):549-51. PubMed ID: 18363539
[TBL] [Abstract][Full Text] [Related]
40. Rosuvastatin-induced rhabdomyolysis probably via CYP2C9 saturation.
Gallelli L; Ferraro M; Spagnuolo V; Rende P; Mauro GF; De Sarro G
Drug Metabol Drug Interact; 2009; 24(1):83-7. PubMed ID: 19354002
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
